Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692811 | 0.85 | KCNH2 (0.51) | RXFP1ALDH1A1TSHR | |
| SCHEMBL7841422 | 0.82 | MAPK1 (0.45) | MAPK1RXFP1CNR2CYP1A2CYP3A4 | |
| SCHEMBL6766761 | 0.80 | MAPK1 (0.45) | MAPK1RXFP1LMNACNR2CYP1A2 | |
| SCHEMBL6666276 | 0.79 | EGLN1 (0.47) | MAPK1RXFP1CNR2CYP1A2CYP3A4 | |
| SCHEMBL6697405 | 0.79 | EGLN1 (0.47) | LMNAALDH1A1TSHRSMN1; SMN2EGLN1 | |
| SCHEMBL6696378 | 0.79 | EGLN1 (0.47) | LMNAALDH1A1TSHRSMN1; SMN2EGLN1 | |
| SCHEMBL6691160 | 0.78 | LMNA (0.47) | LMNAALDH1A1TSHRSMN1; SMN2EGLN1 | |
| SCHEMBL6713866 | 0.77 | EGLN1 (0.46) | MAPK1RXFP1LMNACNR2CYP1A2 | |
| SCHEMBL6695156 | 0.76 | ADORA2A (0.57) | LMNAALDH1A1TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL6699580 | 0.75 | EGLN1 (0.43) | LMNAALDH1A1TSHRSMN1; SMN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| EP-1265896-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6413958-B2 | FOR TREATMENT/PREVENTION OF INFECTION OF HERPES SIMPLEX VIRUS, VARICELLA ZOSTER VIRUS, HUMAN CYTOMEGALOVIRUS, OR EPSTEIN-BARR VIRUS; ENZYME INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2002-07-02 | — | — | US | claimed |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | claimed |
| WO-2001070742-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| EP-1265896-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6413958-B2 | FOR TREATMENT/PREVENTION OF INFECTION OF HERPES SIMPLEX VIRUS, VARICELLA ZOSTER VIRUS, HUMAN CYTOMEGALOVIRUS, OR EPSTEIN-BARR VIRUS; ENZYME INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| WO-2001070742-A1 | 4-HYDROXY-1,8-NAPHTHYRIDINE-3-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007066-A1 | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents | CNR1, HAVCR2, NR1H4 | MAPK1 3165/4885RXFP1 2426/4885LMNA 1449/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | MAPK1 737/4885RXFP1 153/4885LMNA 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.